802 related articles for article (PubMed ID: 15692471)
1. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
Prodanovich S; Ma F; Taylor JR; Pezon C; Fasihi T; Kirsner RS
J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
[TBL] [Abstract][Full Text] [Related]
2. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.
Whittle SL; Hughes RA
Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199
[TBL] [Abstract][Full Text] [Related]
3. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
[TBL] [Abstract][Full Text] [Related]
4. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
5. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
Salim A; Tan E; Ilchyshyn A; Berth-Jones J
Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
8. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement.
Hornung N; Ellingsen T; Stengaard-Pedersen K; Poulsen JH
J Rheumatol; 2004 Dec; 31(12):2374-81. PubMed ID: 15570637
[TBL] [Abstract][Full Text] [Related]
9. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
Hoekstra M; van de Laar MA; Bernelot Moens HJ; Kruijsen MW; Haagsma CJ
J Rheumatol; 2003 Nov; 30(11):2325-9. PubMed ID: 14677172
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation.
Jensen OK; Rasmussen C; Mollerup F; Christensen PB; Hansen H; Ekelund S; Thulstrup AM
J Rheumatol; 2002 Aug; 29(8):1615-8. PubMed ID: 12180718
[TBL] [Abstract][Full Text] [Related]
11. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
12. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
13. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital.
de Thurah A; Nørgaard M; Johansen M; Stengaard-Pedersen K
Scand J Rheumatol; 2010; 39(1):19-25. PubMed ID: 20132066
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
Kent PD; Luthra HS; Michet C
J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
[TBL] [Abstract][Full Text] [Related]
15. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
Wolfe F; Michaud K
Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate update.
Kremer JM
Scand J Rheumatol; 1996; 25(6):341-4. PubMed ID: 8996467
[TBL] [Abstract][Full Text] [Related]
17. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate.
Carroll GJ; Thomas R; Phatouros CC; Atchison MH; Leslie AL; Cook NJ; D'Souza I
J Rheumatol; 1994 Jan; 21(1):51-4. PubMed ID: 8151587
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis.
McKendry RJ; Dale P
J Rheumatol; 1993 Nov; 20(11):1850-6. PubMed ID: 8308769
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
McLean-Tooke A; Aldridge C; Waugh S; Spickett GP; Kay L
Rheumatology (Oxford); 2009 Aug; 48(8):867-71. PubMed ID: 19447771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
